National Research Council, Institute of Cell Biology and Neurobiology, Campus A. Buzzati-Traverso, Monterotondo (Roma), Italy.
Biology Department, IRBM Science Park SpA, Pomezia, Italy.
Parasit Vectors. 2018 Dec 27;11(1):668. doi: 10.1186/s13071-018-3268-8.
Novel anti-schistosomal multi-stage drugs are needed because only a single drug, praziquantel, is available for the treatment of schistosomiasis and is poorly effective on larval and juvenile stages of the parasite. Schistosomes have a complex life-cycle and multiple developmental stages in the intermediate and definitive hosts. Acetylation and deacetylation of histones play pivotal roles in chromatin structure and in the regulation of transcription in eukaryotic cells. Histone deacetylase (HDAC) inhibitors modulate acetylation of several other proteins localized both in the nucleus and in the cytoplasm and therefore impact on many signaling networks and biological processes. Histone post-translational modifications may provide parasites with the ability to readily adapt to changes in gene expression required for their development and adaptation to the host environment. The aim of the present study was to screen a HDAC class I inhibitor library in order to identify and characterize novel multi-stage hit compounds.
We used a high-throughput assay based on the quantitation of ATP in the Schistosoma mansoni larval stage (schistosomula) and screened a library of 1500 class I HDAC inhibitors. Subsequently, a few hits were selected and further characterized by viability assays and phenotypic analyses on adult parasites by carmine red and confocal microscopy.
Three compounds (SmI-124, SmI-148 and SmI-558) that had an effect on the viability of both the schistosomula larval stage and the adult worm were identified. Treatment with sub-lethal doses of SmI-148 and SmI-558 also decreased egg production. Moreover, treatment of adult parasites with SmI-148, and to a lesser extent Sm-124, was associated with histone hyperacetylation. Finally, SmI-148 and SmI-558 treatments of worm pairs caused a phenotype characterized by defects in the parasite reproductive system, with peculiar features in the ovary. In addition, SmI-558 induced oocyte- and vitelline cell-engulfment and signs of degeneration in the uterus and/or oviduct.
We report the screening of a small HDAC inhibitor library and the identification of three novel compounds which impair viability of the S. mansoni larval stage and adult pairs. These compounds are useful tools for studying deacetylase activity during parasite development and for interfering with egg production. Characterization of their specificity for selected S. mansoni versus human HDAC could provide insights that can be used in optimization and compound design.
由于仅有一种药物吡喹酮可用於治疗血吸虫病,且对寄生虫的幼虫和幼体阶段效果不佳,因此需要新型抗血吸虫多阶段药物。血吸虫具有复杂的生活史和中间宿主和终末宿主中的多个发育阶段。组蛋白的乙酰化和去乙酰化在真核细胞的染色质结构和转录调控中起关键作用。组蛋白去乙酰化酶(HDAC)抑制剂调节定位于细胞核和细胞质中的几种其他蛋白质的乙酰化,因此影响许多信号转导网络和生物学过程。组蛋白翻译後修饰可能使寄生虫能够轻易适应其发育和适应宿主环境所需的基因表达变化。本研究的目的是筛选一组 HDAC 类 I 抑制剂文库,以鉴定和表征新型多阶段命中化合物。
我们使用一种基于定量检测曼氏血吸虫幼虫期(尾蚴)中 ATP 的高通量测定法,筛选了 1500 种类 I HDAC 抑制剂文库。随后,选择了一些命中化合物,并通过对成虫进行台盼蓝活细胞计数和胭脂红染色以及共聚焦显微镜观察表型分析进一步进行了表征。
鉴定出了三种化合物(SmI-124、SmI-148 和 SmI-558),它们对幼虫期尾蚴和成虫的活力均有影响。亚致死剂量的 SmI-148 和 SmI-558 处理也降低了产卵量。此外,用 SmI-148 处理成虫,在较小程度上用 Sm-124 处理,与组蛋白超乙酰化有关。最後,用 SmI-148 和 SmI-558 处理虫对会导致一种以寄生虫生殖系统缺陷为特征的表型,在卵巢中具有特殊特征。此外,SmI-558 诱导卵母细胞和卵黄细胞吞噬,并在子宫和/或输卵管中出现退化迹象。
我们报告了对一小部分 HDAC 抑制剂文库进行筛选,并鉴定出三种新型化合物,它们可损害曼氏血吸虫幼虫期和成虫对的活力。这些化合物是研究寄生虫发育过程中去乙酰化酶活性和干扰产卵的有用工具。它们对选定的曼氏血吸虫与人 HDAC 的特异性的特征可提供可用於优化和化合物设计的见解。